[1] 傅剑华,杨弘.食管癌术前新辅助治疗原则及循证医学依据.中国癌症杂志,2011,21:518-521. [2] Medical research council oesophageal cancer working group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.Lancet,2002,359:1727-1733. [3] Allum WH,Stenning SP,Bancewicz J,et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.J Clin Oncol,2009,27:5062-5067. [4] Kelsen DP,Ginsberg R,Pajak TF,et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med,1998,339:1979-1984. [5] Ancona E,Ruol A,Santi S,et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized,controlled trial of preoperative chemotherapy versus surgery alone. Cancer,2001,91: 216-2174. [6] Gebski V,Burmeister B,Smithers BM,et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol,2007,8:226-234. [7] 温登瑰,张健慧,赵秀清,等.术前放疗提高中晚期食管癌生存率随访结果报道.中国肿瘤临床,2004,31:1209-1212. [8] 欧广飞,汪楣,王绿化,等.食管癌术前放疗后病理反应与预后的关系.中华肿瘤杂志,2003,25:74-77. [9] Arnott SJ,Duncan W,Kerr GR,et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol,1992,24: 108-113. [10] 汪楣,谷铣之,黄国俊.食管癌术前放射治疗的前瞻性临床研究.中华放射肿瘤学杂志,2001,10:168-171. [11] Arnott SJ,Duncan W,Gignoux M,et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev,2005,19:CD001799. [12] Schwer AL,Ballonoff A,McCammon R,et al. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance,epidemiology,and end-results study. Int J Radiat Oncol Biol Phys,2009,73:449-455. [13] Urba SG,Orringer MB,Ianettonni M,et al. Concurrent cisplatin,paclitaxe,and radiotherapy as reoperative treatment for Patients with locoregional esophageal carcinoma. Cancer,2006,101:2177-2183. [14] 杨弘,傅剑华,胡讳,等.术前放化疗并手术治疗局部晚期食管癌,中华医学杂志,2008,88:3128-3185. [15] 杨弘,傅剑华,刘孟中,等.术前放化疗并手术治疗局部晚期食管鳞癌的多中心随机对照临床研究.中华医学杂志,2012,17:1028-1032. [16] Gaast AV,Hagen P,Hulshof M,et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase Ⅲ study. J Clin Oncol,2010,28 Suppl: abstr 4004. [17] Burmeister BH,Thomas JM,Burmeister EA,et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase Ⅱ trial. Eur J Cancer,2011,47:354-360. [18] Walsh TN. Oesophageal cancer: who needs neoadjuvant therapy? Lancet Oncol,2011,12:615-616. [19] Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol,2011,12:681-692. [20] Kim T,Grobmyer SR,Smith R,et al. Esophageal cancer: the five year survivors. J Surg Oncol,2011,103:179-183. [21] Boone J,van Hillegersberg R,Offerhaus GJ,et al. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus,2009,22:496-504. [22] 梁朝晖,张维彬,胡少为,等.食管癌组织中表皮生长因子受体和上皮钙粘附素的表达及其临床意义.实用医学杂志,2009,25:1249-1251. [23] Ruhstaller T,Pless M,Dietrich D,et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable,locally advanced esophageal carcinoma: a prospective,multicenter phase ⅠB/Ⅱ trial(SAKK 75/06). J Clin Oncol,2011,29:626-631. [24] Rodriguez CP,Adelstein DJ,Rice TW,et al. A phase Ⅱ study of perioperative concurrent chemoradiotherapy,gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol,2010,5:229-235. [25] Juergens RA,Gibson MK,Yang SC,et al. Phase Ⅱ study of neoadjuvant and adjuvant gefitinib(G) with neoad-juvant chemoradiotherapy(CRT) in operable esophageal adenocarcinoma(EAC).J Clin Oncol,2010,28:4532. [26] Zhi H,Wang L,Zhang J,et al. Significance of COX-2 expressionin human esophageal squamous cell carcinoma．Carcinogenesis,2006,27:1214-1221. [27] Akutsu Y,Hanari N,Yusup G,et al. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol,2011,18:2946-2951. [28] Altorki NK,Christos P,Port JL,et al. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J Thorac Oncol,2011,6:1121-1127.
2013, Vol. 22 
